81 related articles for article (PubMed ID: 11605053)
1. Fibroblast growth factor receptor 3 S249C mutation in virus associated squamous cell carcinomas.
Shotelersuk V; Ittiwut C; Shotelersuk K; Triratanachat S; Poovorawan Y; Mutirangura A
Oncol Rep; 2001; 8(6):1301-4. PubMed ID: 11605053
[TBL] [Abstract][Full Text] [Related]
2. Fibroblast growth factor receptor 3 (FGFR3) - analyses of the S249C mutation and protein expression in primary cervical carcinomas.
Dai H; Holm R; Kristensen GB; Abeler VM; Børresen-Dale AL; Helland A
Anal Cell Pathol; 2001; 23(2):45-9. PubMed ID: 11904459
[TBL] [Abstract][Full Text] [Related]
3. Somatic mutations of fibroblast growth factor receptor 3 (FGFR3) are uncommon in carcinomas of the uterine cervix.
Wu R; Connolly D; Ngelangel C; Bosch FX; Muñoz N; Cho KR
Oncogene; 2000 Nov; 19(48):5543-6. PubMed ID: 11114733
[TBL] [Abstract][Full Text] [Related]
4. Analysis of fibroblast growth factor receptor 3 S249C mutation in cervical carcinoma.
Yee CJ; Lin O; Boyd J
J Natl Cancer Inst; 2000 Nov; 92(22):1848-9. PubMed ID: 11078763
[No Abstract] [Full Text] [Related]
5. Recurrent FGFR3-TACC3 fusion gene in nasopharyngeal carcinoma.
Yuan L; Liu ZH; Lin ZR; Xu LH; Zhong Q; Zeng MS
Cancer Biol Ther; 2014; 15(12):1613-21. PubMed ID: 25535896
[TBL] [Abstract][Full Text] [Related]
6. Frequency of fibroblast growth factor receptor 3 mutations in sporadic tumours.
Sibley K; Stern P; Knowles MA
Oncogene; 2001 Jul; 20(32):4416-8. PubMed ID: 11466624
[TBL] [Abstract][Full Text] [Related]
7. Detection of Epstein-Barr virus-derived latent membrane protein-1 gene in various head and neck cancers: is it specific for nasopharyngeal carcinoma?
Tsang NM; Chang KP; Lin SY; Hao SP; Tseng CK; Kuo TT; Tsai MH; Chung TC
Laryngoscope; 2003 Jun; 113(6):1050-4. PubMed ID: 12782821
[TBL] [Abstract][Full Text] [Related]
8. Incidence of fibroblast growth factor receptor 3 gene (FGFR3) A248C, S249C, G372C, and T375C mutations in bladder cancer.
Dodurga Y; Tataroglu C; Kesen Z; Satiroglu-Tufan NL
Genet Mol Res; 2011 Jan; 10(1):86-95. PubMed ID: 21264819
[TBL] [Abstract][Full Text] [Related]
9. A20 RNA expression is associated with undifferentiated nasopharyngeal carcinoma and poorly differentiated head and neck squamous cell carcinoma.
Codd JD; Salisbury JR; Packham G; Nicholson LJ
J Pathol; 1999 Apr; 187(5):549-55. PubMed ID: 10398120
[TBL] [Abstract][Full Text] [Related]
10. Fibroblast growth factor receptor (FGFR) alterations in squamous differentiated bladder cancer: a putative therapeutic target for a small subgroup.
Baldia PH; Maurer A; Heide T; Rose M; Stoehr R; Hartmann A; Williams SV; Knowles MA; Knuechel R; Gaisa NT
Oncotarget; 2016 Nov; 7(44):71429-71439. PubMed ID: 27669755
[TBL] [Abstract][Full Text] [Related]
11. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors.
Billerey C; Chopin D; Aubriot-Lorton MH; Ricol D; Gil Diez de Medina S; Van Rhijn B; Bralet MP; Lefrere-Belda MA; Lahaye JB; Abbou CC; Bonaventure J; Zafrani ES; van der Kwast T; Thiery JP; Radvanyi F
Am J Pathol; 2001 Jun; 158(6):1955-9. PubMed ID: 11395371
[TBL] [Abstract][Full Text] [Related]
12. No evidence for fibroblast growth factor receptor 3 (FGFR-3) R248C/S249C mutations in human prostate cancer.
Naimi B; Latil A; Berthon P; Cussenot O
Int J Cancer; 2000 Aug; 87(3):455-6. PubMed ID: 10897055
[No Abstract] [Full Text] [Related]
13. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome.
van Rhijn BW; Vis AN; van der Kwast TH; Kirkels WJ; Radvanyi F; Ooms EC; Chopin DK; Boevé ER; Jöbsis AC; Zwarthoff EC
J Clin Oncol; 2003 May; 21(10):1912-21. PubMed ID: 12743143
[TBL] [Abstract][Full Text] [Related]
14. Targeting the extracellular domain of fibroblast growth factor receptor 3 with human single-chain Fv antibodies inhibits bladder carcinoma cell line proliferation.
Martínez-Torrecuadrada J; Cifuentes G; López-Serra P; Saenz P; Martínez A; Casal JI
Clin Cancer Res; 2005 Sep; 11(17):6280-90. PubMed ID: 16144932
[TBL] [Abstract][Full Text] [Related]
15. Generation of monoclonal antibody targeting fibroblast growth factor receptor 3.
Gorbenko O; Ovcharenko G; Klymenko T; Zhyvoloup O; Gaman N; Volkova D; Gout I; Filonenko V
Hybridoma (Larchmt); 2009 Aug; 28(4):295-300. PubMed ID: 19663703
[TBL] [Abstract][Full Text] [Related]
16. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate.
van Rhijn BW; Lurkin I; Radvanyi F; Kirkels WJ; van der Kwast TH; Zwarthoff EC
Cancer Res; 2001 Feb; 61(4):1265-8. PubMed ID: 11245416
[TBL] [Abstract][Full Text] [Related]
17. Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma.
Sibley K; Cuthbert-Heavens D; Knowles MA
Oncogene; 2001 Feb; 20(6):686-91. PubMed ID: 11314002
[TBL] [Abstract][Full Text] [Related]
18. Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth.
Gómez-Román JJ; Saenz P; Molina M; Cuevas González J; Escuredo K; Santa Cruz S; Junquera C; Simón L; Martínez A; Gutiérrez Baños JL; López-Brea M; Esparza C; Val-Bernal JF
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):459-65. PubMed ID: 15701828
[TBL] [Abstract][Full Text] [Related]
19. Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans.
Logié A; Dunois-Lardé C; Rosty C; Levrel O; Blanche M; Ribeiro A; Gasc JM; Jorcano J; Werner S; Sastre-Garau X; Thiery JP; Radvanyi F
Hum Mol Genet; 2005 May; 14(9):1153-60. PubMed ID: 15772091
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of FGFR3 in HPV-positive Tonsillar and Base of Tongue Cancer Is Correlated to Outcome.
Bersani C; Haeggblom L; Ursu RG; Giusca SE; Marklund L; Ramqvist T; Näsman A; Dalianis T
Anticancer Res; 2018 Aug; 38(8):4683-4690. PubMed ID: 30061236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
